Elicit Plant Appoints Pam Marrone and Johan de Saegher on Its Board of Directors
Elicit Plant, an agricultural biotechnology company specialized in crops’ resistance to water stress based on a phytosterol-based technology platform, announced today it has appointed Dr. Pam Marrone as Chairwoman of the Board of Directors and Dr. Johan de Saegher as Independent Board Member.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230301005582/en/
Pam Marrone and Johan de Saegher join Elicit Plant's Board of Directors (Photo: Elicit Plant)
Pam is a serial entrepreneur bringing over 30 years of leadership experience in the agricultural biologicals industry. Pam currently serves as Executive Chair of Invasive Species Control Corporation which she cofounded in 2022. Recently, she was Chief Executive Officer of Marrone Bio Innovations (MBI), an agricultural biological company she founded in 2006. In 2013, MBI listed its stock on NASDAQ. Under her leadership, the company commercialized 10 products from six EPA-registered active ingredients, and in 2019 acquired ProFarm Technologies selling bionutrient seed treatments from wood waste. Prior to establishing MBI, Marrone founded AgraQuest in 1995, where she served as CEO, Chairwoman or President until 2006. Pam is a well-recognized leader as evidenced by numerous awards, including the American Chemical Society’s “Kathryn C. Hach Award for Entrepreneurial Success,” “Most Admired CEO, Distinguished Career Award” by the Sacramento Business Journal, the “Sustie” award by the Ecological Farming Association, and the Natural Resources Defense Council (NRDC) Growing Green Award in the “Business Leader” category. Pam is the founder of the Biological Products Industry Alliance, now a trade group of more than 100 companies. Aside from her role as Chairwoman of Elicit Plant, Pam serves on several for-profit and non-profit Boards, including 180 Life Sciences (NASDAQ: ATNF), StemExpress, Pheronym and the Foundation for Food and Agriculture Research.
Johan de Saegher is an accomplished business executive with 30 years of business experience of which 17 years in the crop protection industry. He currently serves as CEO of Bi-PA, a company specialized in developing innovative solutions for pest management. From 2018 to 2022 he held the position of CEO and COO of Belchim Crop Protection NV, a leading European distributor in the crop protection market, based in Belgium, with also activities in North America and Asia. Previously, and until the company was acquired by Eastman Chemical in 2014, Johan worked at Taminco (NYSE) where he held positions as Chief Operating Officer, Vice-President Agrosciences and President Asia/Latin America. He is currently also Chairman of Aphea.bio and holds a board position within Mitsui Agrisciences International.
“I am impressed by the excellent achievements Elicit Plant has accomplished in such a short time. The company’s unique technology platform positively impacts the planet and provides farmers with a natural and efficient solution to address the challenges of climate change. I am looking forward to work alongside the team as it accelerates its growth,” said Pam Marrone.
Johan de Saegher added, “It is an honor to join Elicit Plant’s Board of Directors and contribute to building the company into a large scale and profitable enterprise as it is entering its next phase of development. Through its high value solutions, Elicit Plant offers for row crops a new dimension in abiotic stress management such as drought, safeguarding the yield of the farmer by optimizing the natural response of the plants to the changing environment.”
Jean-François Dechant, Chief Executive Officer and Cofounder of Elicit Plant, said: “Pam and Johan are a wonderful addition as Elicit Plant is entering new markets, expanding its laboratories and diversifying its portfolio of products. At such a strategic time for Elicit Plant, we are grateful for their confidence, and we are all eager to benefit from their knowledge and impressive track records.”
About Elicit Plant
Elicit Plant is an agbiotech company created in 2017 with the ambition to become a sustainability transition champion in agriculture and respond to the global challenges of water stress in crops. Based in Charente (France), the firm has 60 employees across its R&D Center established within a 1,000 ha farm, its offices in Lyon, and its subsidiary in Brazil. Elicit Plant’s proprietary technology is delivered through foliar application of phytosterols, molecules found in plants that reduce crops’ water consumption. Open-field trials have shown an average yield increase of +10 bushels per acre on average. In 2022, Elicit Plant began marketing its BEST-a product line for corn crops in France, and obtained market approvals for Ukraine and Brazil.
For more information: www.elicit-plant.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005582/en/
Contact information
Media contact for Elicit Plant
Anne Rein
Strategies & Image (S&I)
+33 6 03 35 92 05
anne.rein@strategiesimage.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NextPower V ESG Reaches $745 Million To Date29.4.2024 09:30:00 EEST | Press release
NextEnergy Capital (“NEC”), a leading global renewables manager specialised on the solar+ infrastructure sector, is delighted to announce the conclusion of its second close of $265 million for its fifth strategy, NextPower V ESG (“NPV ESG”). NPV ESG is an OECD-focused solar and battery storage strategy targeting $1.5 billion with a $2 billion hard cap that has secured $745 million in total commitments to date. The new capital includes commitments from a UK LGPS investment pool, a Dutch pension fund, and another re-up from an existing NextPower III ESG investor. These new investors join existing NPV ESG investors KLP, a German occupational pension fund, and a large Nordic pension fund. NPV ESG will continue welcoming further capital, with several investors currently active in due diligence. NPV ESG’s investment strategy targets the solar+ infrastructure sector in carefully selected OECD markets, with the objective of building significant portfolios in each target market, establishing an
H2SITE’s AMMONIA to H2POWER Technology Receives Approval in Principle From Lloyd’s Register29.4.2024 09:30:00 EEST | Press release
Ammonia cracking is gaining momentum as a potential hydrogen carrier for onboard applications and this system is based on H2SITE’s hydrogen-selective membranes that overcome the thermodynamic limitations of the ammonia cracking reaction by recovering hydrogen continuously and resulting in virtually complete ammonia conversion and higher efficiencies at lower temperatures, reducing overall energy consumption and footprint. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240428422597/en/ (Photo: Business Wire) In awarding the AIP, the design and arrangement evaluation included an overall examination of fundamental aspects of the design and compliance with LR’s Rules and Regulations for the Classification of Ships using Gases or other Low-flashpoint Fuels. A preliminary appraisal of rules was undertaken, followed by a risk assessment conducted to ensure that the risks arising from the use of ammonia and hydrogen are addressed ac
Geopolitical Stability, Inclusive Growth, Energy Security Under Spotlight in Riyadh at World Economic Forum Special Meeting29.4.2024 08:46:00 EEST | Press release
Riyadh convened global leaders today at the World Economic Forum Special Meeting on Global Collaboration, Growth and Energy for Development to host candid dialogues and outline bold steps to tackle the most pressing geopolitical, social and economic challenges facing humanity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240428317713/en/ His Excellency Faisal Alibrahim, Saudi Minister of Economy and Planning, welcomes global leaders to Riyadh for the World Economic Forum Special Meeting on Global Collaboration, Growth and Energy for Development. (Photo: AETOSWire) Speaking at the Special Meeting, His Royal Highness Prince Abdulaziz bin Salman bin Abdulaziz Al Saud, Minister of Energy for Saudi Arabia, said a just and equitable energy transition will only be achieved by using a range of energy sources to diversify the global energy market. Access to secure and reliable energy, he said, is crucial to enabling people and comm
4P-Pharma Announces Total Capital of €15 Million Successfully Secured in Second Closing29.4.2024 07:40:00 EEST | Press release
4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of €15 million in its second closing with participation from private investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424933193/en/ (Graphic: Business Wire) With this funding, 4P-Pharma's shareholders renew their confidence in the company's drug regeneration model for untreated serious diseases. They welcome the entry of Phase 2 clinical development of the two first 4P-Pharma's SPVs, underlying the robust potential of the company's business model. Revital Rattenbach, CEO of 4P-Pharma: "As CEO of 4P-Pharma, I am pleased with the renewed trust of our investors placed in our scientific and development approach year after year. This financial endorsement underscores our significant progress over the past decade. It attests to the str
PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA29.4.2024 07:17:00 EEST | Press release
PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx. PPI PathFinder BCL2 Dx incorporates PROTEINA’s “SPID (Single-molecule Protein Interaction Detection)” technology, enabling high-sensitivity detection of protein-protein interaction (PPI) complexes of BCL2 family proteins and more accurate prediction of any PPI inhibitors targeting the BCL2 family. In this clinical validation, PPI PathFinder BCL2 Dx will be used to predict drug responsiveness in patients with Acute Myeloid Leukemia (AML), providing clinicians with guidance for more effective prescriptions of the widespread BCL2-targeted cancer drug “Venetoclax.” PROTEINA has previously conducted clinical validation of the same product domestically with the Hematologic Cancer Team at Seoul National University, and the findings are scheduled to be
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom